

INNOVATIVE, GROUND-BREAKING NEW MEDICINES BASED ON PIONEERING AI

INDUSTRY

New pharmaceuticals for urgent major diseases:
cancer, fibrosis and resistant infections

CUSTOMERS


Patients worldwide suffering serious conditions both in hospitals and community settings

DEMAND

Therapeutic market growing rapidly for new treatments against acute and chronic life-threatening diseases

USE OF FUNDS

Fund business product R&D, pipeline expansion and hiring to cash flow positive



EARLY-STAGE OPPORTUNITY

Company entering first expansion phase after major advances since 2019 with follow-on options

EXPERIENCED TEAM

Management and leadership from top pharmaceutical multinationals with proven expertise in new drug development

DISTINCTIVE HIGHLIGHTS

CORE COMPETENCE I AI

Proprietary pioneering machine learning platform from Oxford University to accelerate new drug discovery

CORE COMPETENCE II SYNTHETASE ENZYMES

World-class expertise in essential enzyme family involved in multiple diseases

SIGNIFICANT GRANT FUNDING

Non-dilutive grants over £9m from foremost international agencies in UK and US validate leading-edge science

